Salspera LLC.

Salspera, Inc. (proposed Nasdaq: TKVA), a Cambridge, Massachusetts-based clinical-stage biopharmaceutical company, filed a prospectus for an initial public offering of 5,666,666 shares of common stock at an expected price range of USD 14.00 to USD 16.00 per share. At the midpoint Salspera IPO price of USD 15.00, the offering would generate approximately USD 85 million in gross proceeds. The funding will support the company’s development of a live biopharmaceutical platform using genetically modified Salmonella Typhimurium to deliver immunotherapeutic agents directly into tumor microenvironments, with a lead candidate currently entering Phase III development in Stage IV metastatic pancreatic cancer. Salspera expects to issue around 62.5 million shares of common stock with underwriters granted a 45-day over-allotment option to purchase up to an additional 850,000 shares, which would bring total shares outstanding to 63,388,712 if exercised in full. Net proceeds to the company are estimated at approximately USD 78.44 million after expenses. Salspera will list to the Nasdaq stock market under the ticker symbol “TKVA”, subject to approval. Company overview and pipeline Salspera was established in July 2017, co-founded by Eddie Moradian, PhD, who serves as Chairman and CEO, and Daniel Saltzman, M.D. and PhD, who serves as CMO. Dr. Saltzman originated the company’s technology platform and previously held the position of Chief of Pediatric Surgery at the University of Minnesota. He has authored 30 publications and 17 presentations on bacterial therapeutics. The firm’s live biopharmaceutical platform is based on developing genetically modified Salmonella Typhimurium for the targeted delivery of immunotherapeutic agents into the tumor microenvironment (TME). This approach leverages the natural tumor-homing properties of Salmonella, combined with genetic engineering to express immune-activating payloads, aiming to overcome the immunosuppressive nature of solid tumors and stimulate robust anti-tumor immunity. Salmonella is a facultative anaerobe with a natural propensity to accumulate in hypoxic and necrotic regions of solid tumors after systemic administration, due to the unique metabolic and immune environment of the TME. The company’s lead candidate, Saltikva, is an attenuated strain of Salmonella Typhimurium engineered to express human interleukin-2 (IL-2). The strain is rendered avirulent through deletion of cya and crp genes and lacks the enzyme aspartate semialdehyde dehydrogenase, creating a containment mechanism whereby the bacterium cannot survive without its engineered plasmid. Saltikva is orally administered and designed to increase populations of NK and CD8+ cytotoxic T cells within tumor microenvironments. Salspera has completed a Phase I study evaluating safety of orally administered Saltikva across oncology indications including pancreatic cancer and osteosarcoma. The company subsequently conducted a Phase II clinical trial of Saltikva in combination with modified FOLFIRINOX chemotherapy in patients with Stage IV metastatic pancreatic cancer. In that Phase II study, the company reported lower tumor burden as well as progression-free and overall survival benefits. For context, patients with Stage IV metastatic pancreatic cancer on standard-of-care chemotherapy regimens (GEM/nab-PTX, FOLFIRINOX, or NALIRIFOX) have median overall survival ranging from 10.4 to 11.7 months, according to data cited in the prospectus. Saltikva is now entering Phase III clinical development in Stage IV metastatic pancreatic cancer. A Type C meeting with the FDA provided the company with a framework for the Phase III study design, which is expected to be a randomized, placebo-controlled trial recruiting across the US, EU, Australia, and Israel. The company anticipates patient recruitment could be completed within two years of study initiation, with interim results available as early as two years after commencement. Saltikva holds Orphan Drug Designation and Fast Track Designation from the FDA for Stage IV pancreatic cancer, both granted in May 2022. In November 2025, Saltikva received Orphan Drug Designation from the FDA for osteosarcoma. In osteosarcoma, Salspera has preclinical data for Saltikva from murine and large mammal (canine) models. Salspera has engaged a pediatric oncologist as clinical consultant and plans to work with the Osteosarcoma Institute on a Phase II/III study for patients with relapsed or metastatic osteosarcoma. Another potential indication is for Saltikva is metastatic colorectal cancer, with Salspera planning to develop a clinical protocol and IND for this indication with the goal of initiating a Phase II/III trial. Your email address will not be published. Required fields are marked * Comment * Name * Email * Website

Plus, news about Salspera and Hoba Therapeutics: 🥊 Bimzelx bests Skyrizi in psoriatic arthritis trial: UCB said its IL-17A/F drug Bimzelx showed “statistically significant superiority” over AbbVie’s IL-23 blockbuster Skyrizi on a measure known as ACR50, which tracks patient improvement across a range of criteria including tender and swollen joint counts. That said, Jefferies analysts pointed out that UCB has yet to report data on secondary endpoints that also measured skin clearance. “Until clarification, the unresolved question may temper enthusiasm,” the analysts wrote, as IL-23 “typically performs well” in skin clearance. For now, they said, “the commercial implications appear limited.” — Nicole DeFeudis 💰 Xenon targets $650M: The biotech is looking to sell about 10.5 million shares at $57 each, as well as more than 877,000 warrants. Xenon reported positive Phase 3 data earlier this week for its epilepsy candidate called azetukalner. — Reynald Castaneda 💰 Dianthus’ $625M offering: The company is selling about 7.3 million shares at $81 apiece, plus warrants. The funds will be used for purposes including the company’s R&D pipeline and commercialization plans. — Reynald Castaneda 👀 Little-known biotech eyes IPO: Cambridge, MA-based biotech Salspera seeks about $78 million in net proceeds if it prices at the midpoint of the $14- to $16-a-share range that it’s marketing to investors. It is offering 5.66 million shares for its planned Nasdaq listing as “TKVA.” The biotech is developing live biopharmaceuticals, including a strain of Salmonella that isn’t toxic and is orally delivered. The treatment candidate, called saltikva, has been in Phase 2 in certain patients with metastatic pancreatic cancer. — Kyle LaHucik 🔒 Hoba Therapeutics shutters R&D: The decade-old Danish biotech, founded by Novo Holdings, has ended R&D, according to a LinkedIn post from an employee and another source familiar with the matter. The biotech is in the preclinical stage and is working on candidates for neuropathic pain and sensorineural hearing loss. Hoba last disclosed a $25 million Series A in December 2023. — Kyle LaHucik

Salspera\'s lead candidate is a strain of salmonella bacteria that has been engineered to express interleukin-2.\n Salspera has set out plans for a $91 million IPO to fund the phase 3 study of its bacteria-based cancer therapy.The Cambridge, Massachusetts-based biotech is hoping to offer 5.6 million shares priced between $14 and $16, according to a March 10 Securities and Exchange Commission filing. Assuming the final price lands in the middle of this range, Salspera expects to bring in net proceeds of $78.4 million.Underwriters would also have the option to buy an additional 850,000 shares, which could bring total proceeds up to $91.2 million, Salspera explained in the filing.If the IPO goes ahead, Salspera will list its stock on the Nasdaq under the ticker “TKVA.”Top of the list of spending priorities is the biotech’s lead candidate saltikva, a strain of salmonella bacteria that has been engineered to express the human gene interleukin-2 (IL-2). As IL-2 increases populations of NK and CD8+ cytotoxic T cells in tumors and peripheral blood, the idea is that saltikva therefore acts as an immunotherapy by killing cancer cells.Salspera has already completed a phase 2 study of saltikva in combination with chemotherapy to treat patients with metastatic pancreatic cancer. In that trial, the therapy demonstrated lower tumor burden and increased progression-free survival and overall survival, according to Salspera’s filing.The biotech is now gearing up for phase 3 studies of saltikva in stage 4 pancreatic cancer, an indication where it has received orphan drug and fast-track tags from the FDA. The company’s strategy also includes exploring saltikva’s potential to treat other solid tumors, including osteosarcoma—for which it received an orphan tag in November—and colorectal cancer.Salspera currently only lists two employees: CEO Eddie Moradian, Ph.D., who previously ran biopharma contract research services provider MD Biosciences; and Chief Medical Officer Daniel Saltzman, M.D., who developed the company’s live biotherapeutics platform.After a lull of biotech IPOs in 2025, Salspera is joining a growing list of drug developers voicing an interest in the public markets. CEOs of companies that already made the leap this year told Fierce they had detected a positive change in sentiment toward biotech IPOs in recent months.